SOURCE: The Bedford Report

The Bedford Report

August 26, 2010 08:00 ET

Drug Manufacturers -- How Will Expiring Drug Patents Affect Companies in the Healthcare Sector

Note to Editors: The Following Is an Investment Opinion Being Issued by the

TORONTO--(Marketwire - August 26, 2010) - The Bedford Report examines the outlook for companies in the Biotechnology Industry and has released analyst reports on Gilead Sciences (NASDAQ: GILD), Biogen Idec Inc. (NASDAQ: BIIB), Acorda Therapeutics, Inc. (NASDAQ: ACOR) and Onyx Pharmaceuticals Inc. (NASDAQ: ONXX). Access to the full company reports can be found at

In recent quarters, expiring patents in the product lines of the major pharmaceutical companies has become a hot topic. Over the next five years drug companies are expected to lose several patents. In order to compensate for expiring drug patents drug companies have been focusing on mergers and acquisitions in order to shore up their patent lines.

Like you, we realize that timing is everything. We release daily market updates so you can stay ahead of the crowd and make the best investment decisions to maximize your returns. Take a few minutes to register with us for free at and get exclusive access to our numerous analyst reports and industry newsletters.

Biotech firms in particular have been a beneficiary of this drive to sign agreements with smaller companies. In addition to acquisitions, small biotech companies are expected to benefit from in-licensing activities and collaborations. In recent news Johnson & Johnson acquired Cougar Biotechnology and Mentor Corp. 

Investors can get copies of the full analyst reports on Gilead Sciences, Biogen Idec, Acorda Therapeutics and Onyx Pharmaceuticals by registering for free at

The Bedford Report has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: 

Contact Information